Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Overall survival of patients with EGFR mutation-positive non-small-cell lung cancer treated with erlotinib, gefitinib or afatinib under drug programmes in Poland - real-world data.

Autor: Brzozowska M; Division of Quality Services, Procedures and Medical Standards, Medical University of Lodz, Lodz, Poland., Wierzba W; UHE Satelite Campus in Warsaw, University of Humanities and Economics in Lodz, Poland., Szafraniec-Buryło S; Department of Pharmacoeconomics, Institute of Mother and Child, Warsaw, Poland., Czech M; Department of Pharmacoeconomics, Institute of Mother and Child, Warsaw, Poland., Majkut G; Analysis and Strategy Department, Central Office, National Health Fund, Warsaw, Poland., Połowinczak-Przybyłek J; Chemotherapy Department, Copernicus Memorial Hospital, Medical University of Lodz, Lodz, Poland., Potemski P; Comprehensive Cancer Center and Traumatology, Copernicus Memorial Hospital, Medical University of Lodz, Lodz, Poland., Śliwczyński A; Division of Quality Services, Procedures and Medical Standards, Medical University of Lodz, Lodz, Poland.

Publikováno v: Archives of medical science : AMS [Arch Med Sci] 2019 Jan 22; Vol. 17 (6), pp. 1618-1627. Date of Electronic Publication: 2019 Jan 22 (Print Publication: 2021).